Artivion

Pioneering Heart and Vascular Health with Advanced Surgical Solutions and Biomaterials for All Ages

General Information
Company Name
Artivion
Founded Year
1984
Location (Offices)
Founders / Decision Makers
Steven G. Anderson - Founder, Chairman, President and CEO Amy Horton - Vice President & Chief Accounting Officer Jean F. Holloway - Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary Thomas F. Ackerman - Thomas F. Ackerman Executive Vice President and CFO D. Ashley Lee - EVP, COO & CFO Pat Mackin - President & CEO Marshall Stanton - Senior Vice President, Clinical Research and Chief Medical Officer
Number of Employees
-
Industries
Hardware, Health Care
Funding Stage
Post Ipo Debt
Social Media

Artivion - Company Profile

Artivion is a medical device company founded in 1984 which focuses on pioneering heart and vascular health through advanced surgical solutions and biomaterials. The company's flagship products include the CryoValve SG pulmonary heart valve and the CryoPatch SG pulmonary cardiac patch tissue, both processed with the SynerGraft technology. In addition, they offer a range of surgical adhesives, sealants, and hemostats such as BioGlue, BioFoam, PerClot, and HemoStase. In January 2024, Ares Management made a $350.00M post-IPO debt investment in Artivion, reflecting a strong investor interest. Despite the absence of specific headquarter information, Artivion's notable success in the Hardware and Health Care industries signifies its potential for growth and innovation.

Taxonomy: biological medical devices, surgical adhesives, biomaterials, cardiac reconstruction, vascular reconstruction, implantable devices, human tissue preservation, CryoValve SG pulmonary heart valve, CryoPatch SG pulmonary cardiac patch tissue, SynerGraft technology, BioGlue Surgical Adhesive, BioFoam Surgical Matrix, PerClot, HemoStase, Starch Medical Inc

Funding Rounds & Investors of Artivion (3)

View All
Funding Stage Amount No. Investors Investors Date
Post-IPO Debt $350.00M 1
Ares Management, investor in Artivion's Post-IPO Debt round
18 Jan 2024
Post-IPO Debt $100.00M - 18 Jun 2020
Post-IPO Equity $1.25M - 12 Oct 2010

Latest News of Artivion

View All

No recent news or press coverage available for Artivion.

Similar Companies to Artivion

View All
Uscom - Similar company to Artivion
Uscom Practice-changing, non-invasive cardiovascular and pulmonary devices.
Tennova Healthcare- Turkey Creek Medical Center - Similar company to Artivion
Tennova Healthcare- Turkey Creek Medical Center Providing compassionate care to the Farragut and surrounding communities.
TARA Biosystems - Similar company to Artivion
TARA Biosystems Offering cutting-edge, mature human cardiac tissue models to accelerate the development of safe and effective new medicines.
CARDIVA - Similar company to Artivion
CARDIVA Innovation and Commitment
Eso Technologies - Similar company to Artivion
Eso Technologies Minimally invasive, safe, and accurate esophageal cardiac monitoring—advancing cardiac care for surgical and ICU patients.
Circle Decoration Circle Decoration

Want to dive deeper into Artivion? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now